A. Baker

发表

Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium

Eslie Dennis, Elizabeth G. Walker, Amanda F. Baker, 2013 .

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

Shingo Matsumoto, Katarzyna A Rejniak, James B. Mitchell, 2015, Cancer & metabolism.

Detection of in vivo enzyme activity with CatalyCEST MRI

Vipul R Sheth, Erin A. Maine, A. Baker, 2014, Magnetic resonance in medicine.

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

S. Green, A. Baker, A. List, 2006, Cancer control : journal of the Moffitt Cancer Center.

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase

Yon Hui Kim, G. Powis, A. Baker, 2011, Cancer Chemotherapy and Pharmacology.

The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.

R. Gillies, N. Raghunand, G. Powis, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines

A. Baker, L. Garland, Neale T. Hanke, 2016, Journal of Cancer Research and Clinical Oncology.

Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth.

G. Powis, M. Briehl, A. Baker, 2001, Cancer research.

Tumor Growth Glucocorticoid-induced Apoptosis and Exhibit Increased Net Catalase-overexpressing Thymocytes Are Resistant to Updated Version

G. Powis, M. Briehl, A. Baker, 2001 .

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

S. Green, J. Abbruzzese, D. V. Hoff, 2011, Cancer Chemotherapy and Pharmacology.

A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers

N. Raghunand, D. Kirkpatrick, M. Boice, 2013, Investigational New Drugs.

Modulation of the antioxidant defense during dexamethasone-induced apoptosis in WEHI7.2 mouse lymphoid cells

A. Baker, 1997 .

Decreased antioxidant defence and increased oxidant stress during dexamethasone-induced apoptosis: bcl-2 prevents the loss of antioxidant enzyme activity.

G. Powis, M. Briehl, A. Baker, 1996, Cell death and differentiation.

Drug interactions with the taxanes: clinical implications.

A. Baker, R. Dorr, 2001, Cancer treatment reviews.

Modulation of antioxidant defenses during apoptosis.

M. Briehl, A. Baker, L. Siemankowski, 1997, Oncology research.

Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndrome

A. Baker, A. List, W. Bair, 2006, Leukemia.

A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors

S. Green, D. Kirkpatrick, A. Baker, 2007, Clinical Cancer Research.

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

Chiu-Hsieh Hsu, D. Kirkpatrick, G. Powis, 2006, The Journal of laboratory and clinical medicine.

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

P. Wipf, G. Paine-Murrieta, D. Kirkpatrick, 2005, Molecular Cancer Therapeutics.

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

C. Fenoglio-Preiser, G. Powis, A. Baker, 2005, Clinical Cancer Research.

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

C. Fenoglio-Preiser, C. Blanke, J. Abbruzzese, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin.

G. Powis, M. Berggren, A. Gallegos, 2001, Archives of Biochemistry and Biophysics.

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

G. Powis, A. Baker, L. Kirkpatrick, 2006, Cancer Chemotherapy and Pharmacology.

Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging

Renu M. Stephen, R. Gillies, E. Meuillet, 2012, Experimental biology and medicine.

Evaluation of the “Steal” Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer

R. Gillies, A. Baker, G. Martinez, 2014, PloS one.

Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer

D. Alberts, K. Hatch, R. Nagle, 2010, Clinical Cancer Research.

rexpression of Tumor Vascular Endothelial Growth Factor A Portend an Increased Likelihood of Progression Phase II Trial of Bevacizumab and Erlotinib R esistant Ovarian Cancer

D. Alberts, M. Janicek, A. Baker, 2010 .

Identification of Thioredoxin-Interacting Protein 1 as a Hypoxia-Inducible Factor 1&agr;-Induced Gene in Pancreatic Cancer

D. V. Von Hoff, Huamin Wang, G. Powis, 2008, Pancreas.

Management strategies in pancreatic cancer.

A. Baker, C. Campen, T. Dragovich, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines

A. Baker, Neale T. Hanke, S. Malm, 2015, Journal of Experimental & Clinical Cancer Research.

Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer

D. Alberts, A. Baker, D. Roe, 2013, Investigational New Drugs.

IL-6 Stimulates STAT3 and Pim-1 Kinase in Pancreatic Cancer Cell Lines

Erin A. Maine, A. Baker, Katherine M. Block, 2012, Pancreas.

Modulation of the antioxidant defence as a factor in apoptosis.

M. Briehl, A. Baker, Baker Af, 1996, Cell death and differentiation.

Clinical and economic burden of Richter syndrome in inpatient cases of chronic lymphocytic leukemia within the United States, 2001–2010

G. Skrepnek, A. Baker, W. Tate, 2014, Leukemia & lymphoma.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)

J. Crowley, M. Hidalgo, N. Raghunand, 2014, Cancer Chemotherapy and Pharmacology.

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

Damien J. Ferraro, A. Baker, W. Ammons, 2012, Cancer Chemotherapy and Pharmacology.

A study of hard:soft layer ratios and angular switching in exchange coupled media

D. Allwood, A. Baker, L. Zang, 2009 .

MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts

R. Gillies, A. Baker, G. Martinez, 2016, PloS one.

Reproducibility of Magnetic Resonance Perfusion Imaging

Robert J. Gillies, Mark D. Pagel, Amanda F. Baker, 2014, PloS one.

The Development of Pharmacodynamic Endpoint Models for Evaluation of Therapeutics in Pancreatic Cancer

A. Baker, T. Dragovich, 2010 .

Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent

A. Baker, M. Pagel, C. Howison, 2017, NMR in biomedicine.

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models

Amanda F Baker, A. Baker, L. Garland, 2014, Journal of experimental & clinical cancer research : CR.

Radiosensitization of Hs-766T Pancreatic Tumor Xenografts in Mice Dosed with Dodecafluoropentane Nano-Emulsion-Preliminary Findings.

A. Baker, E. Unger, R. Leos, 2015, Journal of biomedical nanotechnology.

Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI

A. Baker, M. Pagel, C. Howison, 2016, Molecular imaging.

Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

Robert J Gillies, Natarajan Raghunand, R. Gillies, 2005, Neoplasia.

Dynamic Contrast-Enhanced and Diffusion MRI Show Rapid and Dramatic Changes in Tumor Microenvironment in Response to Inhibition of HIF-1 A Using PX-4781

R. Gillies, N. Raghunand, G. Powis, 2005 .

Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models

A. Stopeck, A. Baker, M. Pagel, 2015, Leukemia & lymphoma.

The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response

G. Powis, A. Baker, R. Dorr, 2007, Clinical Cancer Research.

TheAntitumorAgent Imexon Activates Antioxidant Gene Expression : Evidence for an Oxidative Stress Response

G. Powis, A. Baker, R. Dorr, 2007 .

Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.

R. Gillies, J. Galons, Yuguo Li, 2012, Magnetic resonance imaging.

Characterization of carfilzomib-resistant non-small cell lung cancer cell lines

B. Seligmann, A. Baker, M. Marron, 2018, Journal of Cancer Research and Clinical Oncology.

Results from Phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies.

M. Egorin, A. Baker, E. Sharlow, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines

A. Baker, Neale T. Hanke, S. Malm, 2015, Journal of experimental & clinical cancer research : CR.

Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer

A. Baker, D. Roe, Ritu Pandey, 2015, Cancer Microenvironment.

In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

G. Powis, D. Mahadevan, E. Meuillet, 2004, Oncology Research.

Promoting Adoption of the 3Rs through Regulatory Qualification.

John-Michael Sauer, Elizabeth Gribble Walker, Amanda F Baker, 2016, ILAR journal.

Identification of Thioredoxin-Interacting Protein 1 as a Hypoxia-Inducible Factor 1&agr;-Induced Gene in Pancreatic Cancer

D. V. Von Hoff, Huamin Wang, G. Powis, 2008, Pancreas.